

Closing Remarks
Steven Teutsch, M.D., M.P.H.

DR. TEUTSCH: Letters we can certainly write. I think that we did get a lot of reinforcement for some of the things that we have said in the Oversight report and the importance of measurement going forward.

I think there are some follow-up things we can clearly do, because we need to monitor the implementation of that, and take some steps there.

I think in terms of our prioritization of what we need to do, we can have some of that discussion tomorrow. In terms of both short-term and longer-term actions, it has come up in various places in the prioritization process. So we should talk about that. It is not what I will do, it is what we will do.

So I think that we should think about what can be done. Certainly, letters of support are important, but we have a lot in that Oversight report as well as the PGX report that we don't want to have sit on paper. We need to move forward.

DR. MAY: A quick comment and an invitation. NIST is going to have a new director in the next six months or so. Bioscience and health has been identified as a priority. I'm fairly sure the new director will honor that.

Having said that bioscience and health has been identified as a priority, right now we are looking at protein measurement science and medical imaging as being major thrusts. That doesn't mean we aren't going to do other things. So I would certainly extend an invitation for you to have your next meeting at our campus, if you would like. We have nice meeting facilities. It is not as convenient to the airports as down here, but the Metro does run out there in the hinterlands.

So I would invite you to perhaps meet there. I don't know whether we will have a new director, but certainly we can have you speak with the leadership and perhaps you can help to influence some of our future directions.

DR. TEUTSCH: Great. Thanks again to all our speakers.

I want to remind all of you who may not be aware of it, in follow-up to the discussion we just had, the Second International Workshop on Clinical Cytogenetic Arrays is actually going to be a couple of weeks from now, December 15th and 16th at the Natcher Center on the NIH campus.

The goal of that workshop is to continue discussions on standardization of quality control in cytogenetic array and clinical application design, resolution interpretation, and a central database for clinical and research purposes. There is a website for those of you who might be interested in getting more information.

In bringing this session to a close, first of all, in addition to thanking all our speakers for the presentations this afternoon, I want to again express my gratitude to Jim and to the staff and everyone who worked so hard on the patents. We came a long way. We have a long way to go to get to agreement on what we are planning to recommend, but it will be great to get that out for comment. So, thanks, Jim, for your leadership on all of that.

SACGHS Meeting Transcript
December 1, 2008

There is a bus, for those of you headed back to the hotel, leaving from the Third Street side. I think when you go out it is to the left.

We will reconvene tomorrow at 8 o'clock a.m., and Paul Wise will lead us through a discussion of our priorities going forward.

Thanks to everybody. Thanks for a good meeting.